InterCure Ltd.
NASDAQ:INCRDrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $51.63M
- Beta
- 0.57
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.04M
INCR Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
InterCure Ltd.NASDAQ: INCR
Net Receivables · Q4 FY2025 · quarter ended Dec 2025
Net receivables falls 14.4% from a year ago
Net receivables stood at ₪154.47M at the end of Q4 FY2025, down 14.4% from a year earlier. Over 3 fiscal years it compounded at +46.1% a year.
Context
- Net receivables amounted to 22.4% of total assets at the end of Q4 FY2025, down 1.3 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -14.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
ILS · from the balance sheet
- Latest · FY2025
- 154.47M ILS
- Year-over-year change
- -14.4%
- 4-year CAGR
- +42.4%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 154.47M | -14.4% |
| FY2024 | 2024-12-31 | 180.5M | +195.3% |
| FY2023 | 2023-12-31 | 61.12M | +23.5% |
| FY2022 | 2022-12-31 | 49.51M | +31.9% |
| FY2021 | 2021-12-31 | 37.53M | — |
Net Receivables vs competitors
How INCR compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -14.4% is the 4th highest of 8, against a peer median of -20.7%.
- Net receivables amounts to 22.4% of total assets for INCR, versus a peer median of 4.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | ₪154.47M ILS | -14.4% | +46.1% | 22.4% | |
| Mar 2026 | $61.53M USD | -7.2% | +38.3% | 29.1% | |
| Mar 2026 | $57.09M USD | -20.7% | -5.2% | 17.5% | |
| Mar 2026 | $25.51M USD | +39.1% | +1.8% | 7.1% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$3.03M CAD | -37.7% | +12.1% | 13.1% |
| Mar 2026 | CA$340.58K CAD | -1.8% | -13.9% | 1.1% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding INCR) | — | -20.7% | +1.8% | 4.1% | |
Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 196.22M | 232.59M | 101.14M | 78.32M | 46.47M |
| Short-term Investments | 330K | 205K | 187K | 333K | 209K |
| Net Receivables | 37.53M | 49.51M | 61.12M | 180.5M | 154.47M |
| Inventory | 67.88M | 146.5M | 106.29M | 125.33M | 108.06M |
| Other Current Assets | 21.08M | 94.35M | 148.78M | 1.32M | 2.03M |
| Total Current Assets | 336.16M | 527.49M | 418.8M | 391.8M | 316.75M |
| Property, Plant & Equipment (Net) | 86.51M | 103.13M | 97.47M | 105.24M | 102.81M |
| Goodwill | 258.07M | 284.18M | 221.08M | 224.59M | 219.19M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 2.57M | 42.57M | 1.92M | 2.15M | 1.02M |
| Tax Assets | 3.02M | 20.64M | 24.68M | 38.37M | 45.99M |
| Other Non-current Assets | 1K | 0 | 22.65M | 423K | 4.79M |
| Total Non-current Assets | 350.17M | 450.51M | 367.81M | 370.77M | 373.81M |
| Total Assets | 686.32M | 958.01M | 786.61M | 762.57M | 690.55M |
| Account Payables | 64.47M | 126.07M | 78.44M | 77.54M | 68.14M |
| Short-term Debt | 72.28M | 128.03M | 88.19M | 69.44M | 99.8M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.9M | 8.06M | 0 | 0 | 0 |
| Other Current Liabilities | 39.42M | 35.63M | 8.16M | 37.97M | 2.97M |
| Total Current Liabilities | 193.58M | 312.72M | 225.87M | 226.75M | 214.37M |
| Long-term Debt | 11.95M | 99.68M | 82.2M | 113.98M | 59.46M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 223K | 1.03M | 841K | 973K | 881K |
| Total Non-current Liabilities | 33.55M | 123.81M | 103.68M | 138.15M | 79.83M |
| Total Liabilities | 227.13M | 436.53M | 329.55M | 364.9M | 294.2M |
| Common Stock | 623.57M | 632.03M | 643.16M | 658.6M | 675.6M |
| Retained Earnings | (186.47M) | (141.65M) | (204M) | (277.58M) | (314.62M) |
| Accumulated OCI | 2.39M | 2.39M | 15.95M | 15.95M | 15.95M |
| Other Stockholders Equity | 8.54M | 8.54M | 0 | 0 | 19.59M |
| Minority Interest | 11.16M | 20.17M | 1.95M | 702K | (164K) |
| Total Equity | 459.19M | 521.48M | 457.06M | 397.67M | 396.36M |
| Total Debt | 108.91M | 255.16M | 195.68M | 211.4M | 183.01M |
| Net Debt | (87.31M) | 22.57M | 94.54M | 133.09M | 136.55M |
InterCure Ltd.
NASDAQ:INCR
Intrinsic Alpha fair value
Locked
Current Price
$3.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.